Market revenue in 2023 | USD 3,452.5 million |
Market revenue in 2030 | USD 10,176.1 million |
Growth rate | 16.7% (CAGR from 2023 to 2030) |
Largest segment | Chromatography systems |
Fastest growing segment | Filters |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chromatography Systems, Filters, Evaporators, Centrifuges, Dryers |
Key market players worldwide | Merck KGaA, Sartorius AG, GE HealthCare Technologies Inc Common Stock, Thermo Fisher Scientific Inc, Danaher Corp, Repligen Corp, 3M Co, Boehringer Ingelheim, Corning Inc, Lonza Group Ltd, Dover Corp, Asahi Kasei Corp, Eppendorf |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to downstream processing market will help companies and investors design strategic landscapes.
Chromatography systems was the largest segment with a revenue share of 40.61% in 2023. Horizon Databook has segmented the China downstream processing market based on chromatography systems, filters, evaporators, centrifuges, dryers covering the revenue growth of each sub-segment from 2018 to 2030.
Global perspectives for China as one of the major biopharmaceutical providers have changed across the past decade. Previously, China was considered a low-quality manufacturer of biogeneric products that were used solely for its local market. In addition, concerns over contracting problems, intellectual property protection, and management issues created a barrier to manufacture of biologics within the country.
However, currently, China’s capabilities in bioprocessing technology have grown substantially. This is majorly due to substantial investments in quality management of bioprocessing techniques, increase in well-trained industry staff, and focus on hiring & training of local staff to increase manufacturing capabilities. However, China still needs to increase its production capacity for manufacture of biological drugs to support its rapidly emerging domestic market.
For this, the local manufacturers are focused on facility expansion plans by incorporating both single-use technologies and stainless steel equipment. Adoption of single-use technologies initially will help to get new facilities commissioned quickly for manufacturing. Thus, it has gained popularity in newly founded small to medium-sized biotechnology companies in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China downstream processing market , including forecasts for subscribers. This country databook contains high-level insights into China downstream processing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account